Phase 3 trial of Libtayo (cemiplimab) as monotherapy for first-line advanced non-small cell lung cancer stopped early due to highly significant improvement in overall survival
| | |

Phase 3 trial of Libtayo (cemiplimab) as monotherapy for first-line advanced non-small cell lung cancer stopped early due to highly significant improvement in overall survival

On Apr. 27, 2020, Regeneron and Sanofi announced the primary endpoint of overall survival was met in a…